Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00289198 · ClinicalTrials.gov registry record · Phase 3
Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)
A Phase 3 study of Rhinitis, Allergic, Perennial, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 301
- Enrollment target
- 20
- Study locations
NCT00289198: Completed Phase 3 study of Rhinitis, Allergic, Perennial, sponsored by GlaxoSmithKline.
NCT00289198 is a Phase 3 study of Rhinitis, Allergic, Perennial that has completed, run by GlaxoSmithKline. The registered enrollment target is 301 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00289198, a Phase 3 study of Rhinitis, Allergic, Perennial, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 301 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with perennial allergic rhinitis (PAR).
Primary Outcome
TNSS is the sum of symptom scores for rhinorrhea, nasal congestion, nasal itching, and sneezing (each scored on a scale of 0 \[none\] to 3 \[severe\]; total possible score of 0 to 12). The rTNSS is a rating of the severity of symptoms over the previous 12 hours and is performed in morning (AM) and evening (PM). Daily rTNSS is defined as average of the PM rTNSS and the AM rTNSS of the next day prior to AM dosing. The Baseline daily rTNSS is defined as the average of the daily rTNSS over 4 consecu
Conditions Studied
Interventions
- DRUG Placebo
- DRUG FF
Study Locations (20)
Victoria
- GSK Investigational Site - Clayton
- GSK Investigational Site - Melbourne
- GSK Investigational Site - Parkville
Ontario
- GSK Investigational Site - Mississauga
- GSK Investigational Site - Ottawa
- GSK Investigational Site - Toronto
Maryland
- GSK Investigational Site - Baltimore
- GSK Investigational Site - Wheaton
California
- GSK Investigational Site - San Diego
Massachusetts
- GSK Investigational Site - North Dartmouth
Minnesota
- GSK Investigational Site - Minneapolis
Ohio
- GSK Investigational Site - Canton
Rhode Island
- GSK Investigational Site - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 301 participants |
| Start Date | 2006-02-07 |
| Est. Completion | 2006-07-04 |
| Phase | Phase 3 |
What the finished NCT00289198 record still lists
NCT00289198 is an interventional study that assigns participants to a tested intervention. The registered 301 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Rhinitis, Allergic, Perennial appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00289198 names 20 study sites across 15 states, led by Victoria, Ontario, Maryland.
Frequently Asked Questions
What is clinical trial NCT00289198 about?
NCT00289198 is a clinical study titled "Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)". The primary objective of this study is to compare the efficacy and safety of GW685698X 100mcg once daily (QD) aqueous nasal spray with vehicle placebo nasal spray in adult and adolescent subjects (12 years of age and older) with perennial allergic rhinitis (PAR).
What is the current status of trial NCT00289198?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 301 participants. The study started on 2006-02-07. Estimated completion is 2006-07-04.
What conditions does trial NCT00289198 study?
This clinical trial studies the following conditions: Rhinitis, Allergic, Perennial.
What interventions are being tested in trial NCT00289198?
The interventions under investigation include: Placebo (DRUG), FF (DRUG).
Who is sponsoring clinical trial NCT00289198?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00289198 being conducted?
This trial has 20 study locations across California, Maryland, Massachusetts, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rhinitis, Allergic, Perennial
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00289198's enrollment target sits among peer trials
301 1121st of 2000 higher than 879 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05005975 · 301 participants · Phase 3
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
- NCT05722561 · 302 participants · Phase 2
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
- NCT06015737 · 302 participants · Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
- NCT07176273 · 302 participants · NA
Adaptive Decision-making And Personalized Treatment for PTSD (ADAPT-PTSD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI